KindlyMD, Inc. (NASDAQ:KDLY, “KindlyMD”), a leading provider of integrated healthcare services, today announced that on May 18, 2025, holders of a majority of the outstanding common stock of KindlyMD delivered a written consent approving the proposed merger agreement and related transactions with Nakamoto Holdings Inc. (“Nakamoto”), a Bitcoin-native holding company.

Hangzhou, China, May 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced the pricing of a registered offering (the “Offering”) of 10,000,000 ordinary units (the “Ordinary Units”) or pre-funded units (the “Pre-funded Units”) in lieu thereof at an offering price of $0.50 per Ordinary Unit and $0.4995 per Pre-funded Unit. For each Pre-funded Unit sold by the Company, the number of Ordinary Units being offered by ...

HAIFA, Israel, May 21, 2025 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today the public offering of 1,365,450 of its ordinary shares. All of the ordinary shares in the proposed offering will be sold by the Company. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase from the Company an amount of additional ordinary shares of up to 15% of the ordinary shares offered in the public offering at the public offering price, less underwriting discounts and commissions. The ordinary shares offered in this offering ...

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure. ...